We are developing an entirely new class of medicines based on the breakthrough discovery in biology known as RNA interference, or RNAi. In 2018, we received approval for ONPATTRO®, the first-ever RNAi therapeutic to hit the U.S. market. This marked the beginning of our robust, RNAi-based pipeline of therapeutics centered around improving the lives of patients across a wide spectrum of diseases.
We are leading the translation of RNAi as a new class of medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of life-threatening diseases with limited treatment options. Our commitment to innovation and excellence is reflected in everything we do, earning us a leadership position in the science and business of RNAi therapeutics that is recognized worldwide. We come together from dozens of countries. We speak over 20 languages. We have diverse educations, backgrounds, skill sets, and lives. We have a resolute focus on creating innovative medicines.
Alnylam Pride 2019
Rare Disease Day 2019